
Annual report 2025
added 04-04-2026
Koninklijke Philips N.V. EPS Ratio 2011-2026 | PHG
EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.
The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]
EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.
A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.
EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.
Annual EPS Ratio Koninklijke Philips N.V.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 3.67 | 1.31 | 1.27 | 1.16 | 1.78 | 1.58 | 0.68 | - | - | - | - |
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.67 | 0.68 | 1.64 |
References
- Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.
EPS Ratio of other stocks in the Diagnostics research industry
| Issuer | EPS Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Agilent Technologies
A
|
3.98 | $ 115.48 | 0.82 % | $ 35.1 B | ||
|
Centogene N.V.
CNTG
|
-2.06 | - | -6.23 % | $ 30.6 M | ||
|
Burning Rock Biotech Limited
BNR
|
-14.2 | $ 16.2 | -0.61 % | $ 175 M | ||
|
Biodesix
BDSX
|
-0.33 | $ 15.07 | 2.1 % | $ 1.95 B | ||
|
Aspira Women's Health
AWH
|
-0.37 | - | -6.19 % | $ 10.5 M | ||
|
Co-Diagnostics
CODX
|
-35.2 | $ 4.4 | 101.83 % | $ 5.85 M | ||
|
Check-Cap Ltd.
CHEK
|
4.3 | - | - | $ 9.42 M | ||
|
Castle Biosciences
CSTL
|
0.66 | $ 24.84 | -0.84 % | $ 690 M | ||
|
DarioHealth Corp.
DRIO
|
10.1 | $ 8.4 | 3.7 % | $ 33.5 M | ||
|
BioNano Genomics
BNGO
|
-4.85 | $ 1.2 | 0.84 % | $ 6.53 M | ||
|
Akumin
AKU
|
-1.75 | - | -17.87 % | $ 25.9 M | ||
|
Charles River Laboratories International
CRL
|
-2.91 | $ 173.89 | -0.58 % | $ 8.62 B | ||
|
Accelerate Diagnostics
AXDX
|
-0.14 | - | -61.36 % | $ 2.46 M | ||
|
DexCom
DXCM
|
2.14 | $ 62.22 | -0.24 % | $ 24.3 B | ||
|
Fulgent Genetics
FLGT
|
-1.41 | $ 16.82 | 2.31 % | $ 509 M | ||
|
Biomerica
BMRA
|
-2.16 | $ 2.17 | -0.91 % | $ 4.98 M | ||
|
Global Cord Blood Corporation
CO
|
4.12 | - | - | $ 399 M | ||
|
Celcuity
CELC
|
-3.79 | $ 112.63 | -0.27 % | $ 5.27 B | ||
|
Genetic Technologies Limited
GENE
|
-0.08 | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
-1.08 | - | 0.12 % | $ 80.1 M | ||
|
Exact Sciences Corporation
EXAS
|
-1.1 | - | - | $ 19.8 B | ||
|
DermTech
DMTK
|
-3.09 | - | -11.32 % | $ 2.94 M | ||
|
Quest Diagnostics Incorporated
DGX
|
8.87 | $ 198.02 | 0.17 % | $ 22 B | ||
|
Guardant Health
GH
|
-3.32 | $ 93.83 | 2.94 % | $ 11.8 B | ||
|
Enzo Biochem
ENZ
|
-0.51 | - | -8.98 % | $ 14.8 K | ||
|
Lantheus Holdings
LNTH
|
3.46 | $ 76.1 | 0.53 % | $ 5.14 B | ||
|
Biocept
BIOC
|
-1.89 | - | -13.05 % | $ 7.29 M | ||
|
Medpace Holdings
MEDP
|
15.6 | $ 498.34 | 1.81 % | $ 14.4 B | ||
|
Heska Corporation
HSKA
|
-1.92 | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
-24.3 | - | -20.0 % | $ 1.06 M | ||
|
Interpace Biosciences
IDXG
|
5.55 | $ 1.96 | 5.82 % | $ 8.67 M | ||
|
Mettler-Toledo International
MTD
|
42.2 | $ 1 259.94 | -1.11 % | $ 26 B | ||
|
ICON Public Limited Company
ICLR
|
9.6 | $ 114.19 | 2.49 % | $ 9.42 B | ||
|
IDEXX Laboratories
IDXX
|
13.2 | $ 569.55 | 0.87 % | $ 45.8 B | ||
|
Neogen Corporation
NEOG
|
-5.03 | $ 9.41 | 0.21 % | $ 2.04 B | ||
|
Illumina
ILMN
|
-7.69 | $ 127.38 | 0.59 % | $ 20.3 B | ||
|
IQVIA Holdings
IQV
|
7.91 | $ 173.26 | 0.5 % | $ 29.8 B | ||
|
Pacific Biosciences of California
PACB
|
-1.82 | $ 1.34 | -0.74 % | $ 402 M | ||
|
QIAGEN N.V.
QGEN
|
1.96 | - | - | $ 10.6 B | ||
|
Motus GI Holdings
MOTS
|
-15.9 | - | -34.28 % | $ 263 K | ||
|
Chembio Diagnostics
CEMI
|
-0.72 | - | 0.22 % | $ 16.8 M | ||
|
Laboratory Corporation of America Holdings
LH
|
10.5 | $ 273.72 | 0.36 % | $ 22.8 B | ||
|
Myriad Genetics
MYGN
|
-3.95 | $ 4.75 | 3.49 % | $ 440 M | ||
|
Sotera Health Company
SHC
|
0.27 | $ 14.96 | 0.61 % | $ 4.25 B | ||
|
NeoGenomics
NEO
|
-0.84 | $ 8.0 | 3.23 % | $ 1.02 B | ||
|
National Research Corporation
NRC
|
50 | $ 17.16 | -1.04 % | $ 384 M |